EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacology activity, toxicity, and clinical trials of Erythrina genus plants (Fabaceae): an evidence-based review

Elis Susilawati, Jutti Levita, Yasmiwar Susilawati, Sri Adi Sumiwi

Frontiers in Pharmacology · 16.11.2023 · 14

DOI: 10.3389/fphar.2023.1281150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.11.2023. Verfasst von Elis Susilawati und 3 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The concept of using plants to alleviate diseases is always challenging. In West Java, Indonesia, a local plant, named dadap serep has been traditionally used to reduce blood glucose, fever, and edema, by pounding the leaves and applying them on the inflamed skin, or boiled and consumed as herbal tea. This plant belongs to the Erythrina genus, which covers approximately 120 species. The scope of this review (1943–2023) is related to the Global Development Goals, in particular Goal 3: Good Health and Wellbeing, by focusing on the pharmacology activity, toxicity, and clinical trials of Erythrina genus plants and their metabolites, e.g., pterocarpans, alkaloids, and flavonoids. Articles were searched on PubMed and ScienceDirect databases, using “Erythrina” AND “pharmacology activity” keywords, and only original articles written in English and open access were included. In vitro and in vivo studies reveal promising results, particularly for antibacterial and anticancer activities. The toxicity and clinical studies of Erythrina genus plants are limitedly reported. Considering that extensive caution should be taken when prescribing botanical drugs for patients parallelly taking a narrow therapeutic window drug, it is confirmed that no interactions of the Erythrina genus were recorded, indicating the safety of the studied plants. We, therefore, concluded that Erythrina genus plants are promising to be further explored for their effects in various signaling pathways as future plant-based drug candidates.

Schlagwörter

Stichwörter der Autor:innen

Erythrina genusanti-inflammatoryflavonoidspterocarpanstoxicity

Autor:innen und Institutionen

  • Doctoral Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
  • Faculty of Pharmacy, Bhakti Kencana University, Bandung, Indonesia.
  • Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
  • Department of Biology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.

Zitieren

APA

Susilawati, E., Levita, J., Susilawati, Y., & Sumiwi, S. A. (2023). Pharmacology activity, toxicity, and clinical trials of Erythrina genus plants (Fabaceae): an evidence-based review. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1281150

Vancouver

Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Pharmacology activity, toxicity, and clinical trials of Erythrina genus plants (Fabaceae): an evidence-based review. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1281150

BibTeX
@article{Susilawati2023,
  author = {Susilawati, Elis and Levita, Jutti and Susilawati, Yasmiwar and Sumiwi, Sri Adi},
  title = {Pharmacology activity, toxicity, and clinical trials of Erythrina genus plants (Fabaceae): an evidence-based review},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1281150}
}
Kostenlos starten →